Related Experiment Video

Updated: Jun 5, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology

B Glimelius1, M Lahn

  • 1Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 18, 2011
PubMed
Abstract

Insights

Window trials are a safe method to evaluate new molecular entities (NMEs) in cancer patients. These trials help establish antitumor activity without negatively impacting overall survival, with careful monitoring.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Drug Development

Background:

  • New molecular entities (NMEs) like targeted agents and cancer vaccines necessitate optimized clinical trial designs.
  • Window trials offer a unique approach to evaluate NMEs by administering them before standard treatment.

Purpose of the Study:

  • To assess the suitability and safety of window trial designs for evaluating NMEs in oncology.
  • To determine if window trials can improve the approval rates of novel cancer therapies.

Main Methods:

  • A systematic literature search was performed to identify relevant window trials in adult and pediatric oncology.
  • Twenty-nine window trials were reviewed, analyzing their methodologies and outcomes.

Main Results:

  • Window trials successfully established the antitumor activity of several agents (melphalan, topotecan, epirubicin, etoposide) in specific cancers.
  • No significant negative impact on overall survival was observed in window trials involving ineffective or modestly active NMEs.

Conclusions:

  • Window trials are a safe and viable option for investigating the clinical activity of NMEs.
  • Close safety monitoring and careful patient selection are crucial for successful window trial implementation.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...